Theratechnologies Inc. (THTX)

USD 1.77

(9.26%)

Market Cap (In USD)

81.38 Million

Revenue (In USD)

81.76 Million

Net Income (In USD)

-23.95 Million

Avg. Volume

38.11 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.08-2.58
PE
-
EPS
-
Beta Value
1.725
ISIN
CA88338H7040
CUSIP
88338H100
CIK
1512717
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Paul Lévesque
Employee Count
-
Website
https://www.theratech.com
Ipo Date
2009-02-13
Details
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.